甲状腺乳头状癌不确定反应患者的个体化随访策略
本研究纳入403例初始治疗后12-24个月呈不确定反应的甲状腺乳头状癌患者,按风险分为Tg+、TgAb+和Image+三组。中位随访9.6年,结构性疾病持续/复发率为14%,三组分别为26.5%、8.7%和0%。Tg+组预测结构性疾病的最佳刺激后Tg截断值为3.1 ng/mL,该分类系统预测能力优于TNM分期和ATA危险分层。
要点
- 不确定反应患者可分Tg+、TgAb+、Image+三组进行风险分层随访。
- Tg+组结构性疾病风险最高,需更密切评估包括远处转移早期筛查。
- TgAb+或仅影像非特异性发现者,定期监测Tg、TgAb和颈部超声即可。
核心结论
- 对初始治疗后不确定反应的甲状腺乳头状癌患者,建议根据Tg、TgAb和影像学结果进行个体化随访。
研究设计与样本
- 研究纳入403例初始治疗后12-24个月呈不确定反应的甲状腺乳头状癌患者,均行全甲状腺切除加放射性碘残余消融。
- 患者分为Tg+组196例、TgAb+组46例和Image+组161例。
主要发现
- 中位随访9.6年(四分位距7.7-11.2年),56例(14%)出现结构性疾病持续/复发,其中50例(89%)为局部区域,6例(11%)为远处。
- Tg+、TgAb+和Image+组的结构性疾病持续/复发率分别为26.5%、8.7%和0%。
- 从初次甲状腺手术到检出结构性疾病持续/复发的中位时间为3.7年(四分位距2.5-6.3年)。
- Tg+组预测结构性疾病持续/复发的最佳刺激后Tg截断值为3.1 ng/mL。
- 该分类系统预测结构性疾病持续/复发的变异解释比例(15.7%)高于TNM分期(2.4%)和ATA危险分层(0.9%)。
关键数值与推荐
- Tg+组定义为可检测到Tg,无论TgAb或影像学结果如何。
- TgAb+组定义为TgAb阳性且Tg不可检测,无论影像学结果如何。
- Image+组定义为颈部超声非特异性发现或全身扫描甲状腺床淡摄取,且Tg不可检测、TgAb阴性。
临床怎么用
- 对不确定反应患者应进一步分层,Tg+组需更密切评估,包括早期远处转移评估。
- TgAb+或仅影像非特异性发现者,定期随访Tg、TgAb和颈部超声即可。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The concept of a dynamic risk-stratification scheme has been suggested for individualized management of patients with papillary thyroid carcinoma (PTC). However, there is no specified follow-up strategy for patients with an indeterminate response. METHODS: This study evaluated 403 PTC patients who had an indeterminate response during the first 12-24 months after initial therapy. All patients underwent total thyroidectomy with radioactive iodine remnant ablation. Patients were further classified into three groups based on risk of structural persistence/recurrence: a Tg+ group (detectable thyroglobulin [Tg], regardless of antithyroglobulin antibody [TgAb] or imaging findings; 196 patients), a TgAb+ group (positive results for TgAb with undetectable Tg, regardless of imaging findings; 46 patients), and an Image+ group (nonspecific findings on neck ultrasonography or faint uptake in the thyroid bed on whole-body scan, with undetectable Tg and negative results for TgAb; 161 patients). RESULTS: With a median of 9.6 years (interquartile range 7.7-11.2 years) of follow-up, 56 (14%) PTC patients had structural persistent/recurrent disease: 50 (89%) at locoregional sites and six (11%) at distant sites. The recurrence rate in Tg+, TgAb+, and Image + groups were 26.5%, 8.7%, and 0%, respectively. The median time to detection of structural persistent/recurrent disease from the initial thyroid surgery was 3.7 years (interquartile range 2.5-6.3 years). The optimal cutoff stimulated Tg level to predict structural persistent/recurrent disease was 3.1 ng/mL in the Tg+ group. This classification system revealed higher predictability of structural persistent/recurrent disease than the tumor-node-metastasis staging system and American Thyroid Association risk stratification (proportion of variation explained: 15.7% vs. 2.4% and 0.9%, respectively). Six (3%) patients with distant metastatic disease were all classified in the Tg+ group, and all had lung metastasis. CONCLUSIONS: The findings suggest a more individualized follow-up strategy for patients with an indeterminate response. More careful evaluation, including early evaluation of distant metastasis, is necessary in patients with elevated Tg levels. However, for patients testing positive for TgAb or those with only nonspecific imaging findings, regular follow-ups of Tg and TgAb levels and neck ultrasonography are sufficient.
引用
- Oh HS, Ahn JH, Song E, et al. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma. Thyroid. 2018. PMID: 30384812. doi:10.1089/thy.2018.0391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。